



Mouse Anti-Tocilizumab monoclonal antibody, clone 7D21 (CABT-ZB254)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

| | |
|-------------------------|--|
| Product Overview | CABT-ZB254 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Tocilizumab. |
| Specificity | The product is specific for Tocilizumab. |
| Target | Tocilizumab |
| Immunogen | Tocilizumab |
| Isotype | IgG2b |
| Source/Host | Mouse |
| Clone | 7D21 |
| Purification | Protein A purified |
| Conjugate | Unconjugated |
| Applications | Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB253 - CABT-ZB254 Recommended Working Concentration: 0.01-0.1 µg/ml |
| Reconstitution | Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Format | Purified, Lyophilized. |
| Size | 40 µg |

| | |
|---------------------|--|
| Buffer | Lyophilized with PBS, pH 7.4, contains 0.02% sodium azide. |
| Preservative | 0.02% sodium azide |
| Storage | The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles. |
| Ship | Wet ice |

BACKGROUND

| | |
|---------------------|--|
| Introduction | Tocilizumab also known as atlizumab, is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration. It has a high affinity to IL-6R and blocks the IL-6 signaling by preventing the formation of the IL-6/IL-6R complex. Tocilizumab is used for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. |
| Keywords | Mouse monoclonal antibody to Actemra / RoActemra; Tocilizumab; atlizumab |

GENE INFORMATION

| | |
|-----------------|--|
| Synonyms | Mouse monoclonal antibody to Actemra / RoActemra; Tocilizumab; atlizumab |
|-----------------|--|